- Home
- WHWK vs NSPR Comparison
WHWK vs NSPR Comparison
Compare WHWK & NSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WHWK
- NSPR
- Stock Information
- Founded
- WHWK 2007
- NSPR 2005
- Country
- WHWK United States
- NSPR United States
- Employees
- WHWK N/A
- NSPR N/A
- Industry
- WHWK Biotechnology: Pharmaceutical Preparations
- NSPR Medical/Dental Instruments
- Sector
- WHWK Health Care
- NSPR Health Care
- Exchange
- WHWK Nasdaq
- NSPR Nasdaq
- Market Cap
- WHWK 87.6M
- NSPR 75.1M
- IPO Year
- WHWK N/A
- NSPR N/A
- Fundamental
- Price
- WHWK $1.94
- NSPR $2.30
- Analyst Decision
- WHWK
- NSPR Strong Buy
- Analyst Count
- WHWK 0
- NSPR 2
- Target Price
- WHWK N/A
- NSPR $4.50
- AVG Volume (30 Days)
- WHWK 148.4K
- NSPR 389.2K
- Earning Date
- WHWK 08-15-2025
- NSPR 08-05-2025
- Dividend Yield
- WHWK N/A
- NSPR N/A
- EPS Growth
- WHWK N/A
- NSPR N/A
- EPS
- WHWK 0.91
- NSPR N/A
- Revenue
- WHWK $27,775,000.00
- NSPR $7,027,000.00
- Revenue This Year
- WHWK $49.83
- NSPR $4.85
- Revenue Next Year
- WHWK N/A
- NSPR $113.47
- P/E Ratio
- WHWK $2.24
- NSPR N/A
- Revenue Growth
- WHWK 16.51
- NSPR 8.49
- 52 Week Low
- WHWK $1.21
- NSPR $1.99
- 52 Week High
- WHWK $3.81
- NSPR $3.80
- Technical
- Relative Strength Index (RSI)
- WHWK N/A
- NSPR 48.63
- Support Level
- WHWK N/A
- NSPR $2.12
- Resistance Level
- WHWK N/A
- NSPR $2.48
- Average True Range (ATR)
- WHWK 0.00
- NSPR 0.14
- MACD
- WHWK 0.00
- NSPR 0.01
- Stochastic Oscillator
- WHWK 0.00
- NSPR 73.47
About WHWK Whitehawk Therapeutics Inc. Common Stock
Whitehawk Therapeutics Inc is a preclinical stage oncology therapeutics. The company is engaged in applying technologies to established tumor biology to efficiently deliver improved cancer treatments. The company's three-asset ADC portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers.
About NSPR InspireMD Inc.
InspireMD Inc is a United States based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System (MGuard Prime EPS). It generates the majority of the revenue from the sales of CGuard EPS which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The group operates in Italy, Germany, Russia and other countries.